ProPhase Labs (NASDAQ:PRPH) Shares Cross Below 200-Day Moving Average – What’s Next?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.14 and traded as low as $0.13. ProPhase Labs shares last traded at $0.1364, with a volume of 82,635 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

ProPhase Labs Stock Down 0.9%

The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of 0.14. The stock has a 50-day simple moving average of $0.19 and a two-hundred day simple moving average of $2.14. The firm has a market cap of $821,400.80, a PE ratio of -0.03 and a beta of -0.52.

Institutional Trading of ProPhase Labs

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in ProPhase Labs in the second quarter worth approximately $40,000. Apollon Wealth Management LLC purchased a new position in shares of ProPhase Labs during the third quarter worth approximately $84,000. Accretive Wealth Partners LLC purchased a new position in shares of ProPhase Labs during the third quarter worth approximately $114,000. Susquehanna International Group LLP lifted its holdings in shares of ProPhase Labs by 290.1% in the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after acquiring an additional 295,899 shares during the last quarter. Finally, Sykon Capital LLC purchased a new stake in shares of ProPhase Labs in the 2nd quarter valued at $252,000. Institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.